trending Market Intelligence /marketintelligence/en/news-insights/trending/qdcBGFgIp-mDD1qry9Mv1w2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Minerva ends development of depression drug after mid-stage study failure

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Minerva ends development of depression drug after mid-stage study failure

Minerva Neurosciences Inc.'s depression treatment MIN-117 failed to significantly reduce symptoms of depression compared to placebo in patients with major depressive disorder during a mid-stage study.

The Waltham, Mass.-based biotechnology company was evaluating 2.5-milligram and 5-milligram doses of the drug in adult patients with moderate to severe major depressive disorder in the six-week phase 2b trial.

Both doses of the drug failed to reduce symptoms of anxiety over the six-week treatment period.

Minerva Executive Chairman and CEO Remy Luthringer expressed disappointment with the results and said the company has no plans to further develop the drug in the major depressive disorder indication.